Upregulation of CCL19 expression could inhibit CRC angiogenesis by promoting inhibition of the Met/ERK/Elk-1/HIF-1α/VEGF-A pathway by miR-206, suggesting a novel therapeutic strategy for antivascular treatment in CRC [301]. This evidence concerns the gene VEGFA and colorectal carcinoma.